An updated BCR-ABL1 t[9;22] RT-PCR assay went live on Jan 31, 2018. The BCR-ABL major and minor fusion transcripts are measured and reported separately after this update. The quantities of BCR-ABL1 major breakpoints fusion transcripts (type e13a2 and/or e14a2) are detected by FDA approved QuantideX® qPCR BCR-ABL IS Kit and the result is calibrated and reported on the International Scale (%IS). The quantities of BCR-ABL minor fusion transcripts are detected by QuantideX qPCR BCR-ABL minor kit and the result is reported as BCR-ABL1 to ABL1 ratio (%). This update provides more precise and standard measurements of BCR-ABL fusion RNA and supports the consistency of patient care in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).
Questions may be directed to the Molecular Diagnostics Laboratory using the “Contact Us” link above.
Lab Catalog link: LAB3222022: BCR-ABL1 t[9;22] RT- PCR
Per the memo sent out July 2012, the Grand Rapids area laboratories will draw patients after hours on a limited basis at the Butterworth Hospital Laboratory location ONLY. We will serve patients with emergent laboratory needs with a direct physician request. The laboratory will be unable to accommodate routine walk-in patients outside of normal business hours.
The physician will need to call the Laboratory Call Center at 616-774-7721 to initiate the blood draw for their critical needs patient. Please be prepared to provide our Call Center with relevant information regarding the patient’s situation. You will also be asked to fax a written order to 616-391-3129, and should direct your patient to the Butterworth Admitting for the blood draw. Be advised that this process may take up to 30 minutes to complete the draw using our inpatient phlebotomy staff.
We request that all routine blood draws return to one of our convenient Outpatient laboratory locations during normal business hours. Most laboratory locations are open Monday to Friday from 7 a.m. to 5 p.m. We recommend that if there is a question regarding hours of operation to contact the draw site.
Spectrum Health Regional Laboratory is preparing to switch Clostridium difficile testing methods from solely using a molecular approach to a 2-step algorithm utilizing an Enzyme Immunoassay (EIA) that detects two C. difficile-specific proteins (glutamate dehydrogenase or GDH, and A/B toxin) with indeterminant EIA specimens reflexed to PCR (see flowchart below). It is estimated that approximately 90% of patients tested will be resolved by EIA and not require reflexive PCR testing. This algorithm decreases expenses to the patient by an average of 65% as compared to current testing without sacrificing result quality. Specimens will be batched for EIA testing at a frequency to ensure that results are available within 6 hours of receipt by the laboratory so that proper contact isolation precautions may be initiated when indicated.
As of January 30th, 2017 the test for Fecal Leukocytes will be discontinued and replaced with testing for Fecal Lactoferrin.